



Erythrocin™ (erythromycin lactobionate), Marplan® (isocarboxazid) – Drug shortages

- The drug shortages of Hospira's [Erythrocin \(erythromycin lactobionate\)](#) injection and Validus Pharmaceuticals' [Marplan \(isocarboxazid\)](#) tablets are ongoing.
 - [Erythrocin](#) has been unavailable for at least 90 days due to manufacturing delays. The next estimated availability date is September 2018 with an estimated recovery by 2019.
 - [Marplan](#) has been unavailable for at least 90 days due to requirements related to complying with good manufacturing practices. The estimated availability date is unknown at this time.
- Marplan is indicated for the treatment of depression.
- Erythrocin is indicated in the treatment of infections caused by susceptible strains of certain organisms of various diseases when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Erythrocin is also indicated for the prevention of initial attacks of rheumatic fever, prevention of recurrent attacks of rheumatic fever, and for the prevention of bacterial endocarditis.

Product Description	NDC #
Erythrocin (erythromycin lactobionate) 500 mg injection	00409-6482-01; 00409-6476-44
Marplan (isocarboxazid) 10 mg tablets	30698-032-01



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.